Positive results from Phase 3 STELLAR trial evaluating Sotatercept for the treatment of Adults with Pulmonary Arterial Hypertension, October 14, 2022

On October 10, 2022 MERCK released the results from the pivotal Phase 3 STELLAR trial evaluating the safety and efficacy of sotatercept, an investigational activin receptor type IIA-Fc (ActRIIA-Fc) fusion protein being evaluated as an add-on to stable background therapy for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1).

Read more about the STELLAR study on the Merck website at this link

Scroll to Top